Role of stereotactic radiotherapy for head neck cancer

In recent years, stereotactic ablative radiotherapy (SABR) has been created. Using one or a small number of dosage fractions, SABR enables the hypofractionated treatment of extracranial tumours, delivering a high biologically effective dose with little damage. This review article explores role of stereotactic ablative radiotherapy in head neck cancers.

Using the search parameters SABR, stereotactic radiotherapy, and targeted radiation, the publications were found on PubMed and Scopus. For this review, the closest publications to SABR were consulted from the search results that were returned.

In the treatment of patients with recurring and/or previously irradiated head and neck malignancies, SABR is technically possible, well-tolerated, and performs comparably to other salvage therapy options. It also offers the benefit of a quicker course of therapy. Timetable, increased adherence, and secure delivery in the outpatient context. This presents a chance to provide SABR as a therapy option for a limited number of patients. In order to properly administer a highly conformal ablative dosage to targets (or tumours) in the body, SBRT requires sophisticated technologies in radiation planning and imaging guiding. Because of its highly conformal dose distributions and stereotactic spatial precision in administration, SABR is being employed more and more to treat a range of head and neck tumours.